Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (DE:1S9)
:1S9
RESEARCH TOOLSreports
1S9 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.52 - €1.34
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€115.49M
Enterprise Value€204.62M
Total Cash (Recent Filing)$85.82M
Total Debt (Recent Filing)$7.25M
Price to Earnings (P/E)―
Beta0.06
Next Earnings
May 07, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding174,358,750
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1937.83
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
€5.05Price Target Upside689.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Seres Therapeutics News
PremiumCompany Announcements
Seres Therapeutics Advances SER-155 Program with FDA Support
PremiumCompany Announcements
Seres Therapeutics Earnings Call: Progress Amid Uncertainty---
Bulls Say, Bears Say
Bulls Say
FDA SupportThe FDA is supportive of a 30-day endpoint for BloodStream Infections, which is a positive development for the next SER-155 study.
Financial PerformanceSeres has received a $50M installment fee and is set to receive another $23.5M, extending its cash runway into 1Q26.
Partnership OpportunitiesThe progress of the SER-155 study should boost partnership opportunities, with expectations of an upfront payment supporting further research.
Bears Say
Financial StructureSeres currently has $66.8M cash and equivalents, funding their cash runway into 4Q25.
Strategic DecisionsMCRB announced the planned sale of the remainder of Vowst rights to partner Nestle, with payments totaling $75MM expected and potential future sales milestone payments up to $275MM.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.45% Insiders
11.15%
Mutual Funds
13.81% Other Institutional Investors
70.86% Public Companies and
Individual Investors
1S9 FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Seres Therapeutics Inc. lowest stock price was €0.52 and its highest was €1.34 in the past 12 months.
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is €115.49M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is May 07, 2025 which is in 37 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on Mar 13, 2025. The company reported -€0.083 earnings per share for the quarter, beating the consensus estimate of -€0.182 by €0.099.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is 0.03.
How many shares outstanding does Seres Therapeutics Inc. have?
Seres Therapeutics Inc. has 174,358,750 shares outstanding.
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of -€0.083 in its last earnings report, beating expectations of -€0.182. Following the earnings report the stock price went down -12.036%.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Currently, no hedge funds are holding shares in DE:1S9
---
Seres Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.05 (689.47% Upside)
€5.05 (689.47% Upside)
Blogger Sentiment
Bullish
DE:1S9 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.84%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-61.01%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
---
1S9 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects significant progress with SER-155 and financial improvements, balanced by uncertainties in clinical development timelines and leadership transitions.Read More>---
1S9 Stock 12 Month Forecast
Average Price Target
€5.05
▲(689.47% Upside)
Technical Analysis
Amicus
―
Blueprint Medicines
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 1S9
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+118.93%
reiterated a sell rating 8 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +118.93% per trade.
---